Stagwell (NASDAQ:STGW), the challenger network built to transform marketing, today announced it will partner with RealClearPolitics (RCP), an independent, non-partisan media company, to create an enhanced polling
Vuzix® Corporation (NASDAQ:VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, announced that the Company will be broadly showcasing
CyberArk (NASDAQ:CYBR), the identity security company, today announced that Accenture, a leading global professional services company, has expanded its deployment of the CyberArk Identity Security Platform to include
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA,
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term dosing with REL-1017 was